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Objectives: To determine the relative extent to which the National Institute for Health and
Clinical Excellence (NICE) appraises new versus existing technologies, and
pharmaceutical versus nonpharmaceutical health technologies.
Methods: We categorized technologies within NICE appraisals published between March
2000 and June 2006 by type and classified them as new or existing using the timeline
between launch in the United Kingdom and referral to NICE. We used a 3-year postlaunch
cutoff to determine whether a technology was new, with a sensitivity analysis of 1 and
5 years.
Results: We reviewed 159 technologies from 88 appraisals. Of these, 84 (53 percent)
were new (sensitivity analysis 36 to 67 percent) and 75 (47 percent) were existing
technologies. A total of 119 (75 percent) were pharmaceuticals, 22 (14 percent) were
devices, 14 (9 percent) were procedures, and 4 (3 percent) were categorized as
miscellaneous. Classification according to newness and technology type showed that 62
percent (42 to 75 percent) of the pharmaceuticals appraised were new.
Conclusions: By developing and applying a definition of new, we have found that the
criticism of the bias toward new technologies is unfounded when applied to the appraisal
program overall. At the same time, new pharmaceuticals are over-represented in the
program compared with devices and procedures. This domination may cause inflationary
pressures on the health service, but any wholesale move away from the technological
frontier may be more costly.
Keywords: National Institute for Health and Clinical Excellence, Health technology,
Health technology assessment, Topic selection, NICE
The National Institute for Health and Clinical Excellence
(NICE) was established in April 1999 to provide the National
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Health Service (NHS) with guidance on the clinical and cost-
effectiveness of health technologies. In the consultation pa-
pers that heralded its introduction, it was envisaged that both
new and existing technologies would be covered (9), but that
initially the program would focus on new technologies, with
a catch-up program planned for existing technologies once
the program became more established. It was also envisaged
that all types of clinical intervention would be included on
an equal basis (10).
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Figure 1. Cutoff points for referral to National Institute for Health and Clinical Excellence (NICE) used to categorize technologies.
Until summer 2006, appraisal topics were selected by
the English Department of Health (DH). In 2006, NICE was
given responsibility for the initial topic selection with the
final topic selection announced by Ministers (5). Although
NICE had not been responsible for the selection of appraisal
topics, it has faced criticism of an apparent bias toward ap-
praising new technologies, particularly pharmaceuticals, at
the expense of neglecting old ineffective or inefficient tech-
nologies whose removal from practice may offer the opportu-
nity to provide savings for the NHS (3;8;13;14). The concern
is that such a bias toward new technologies is likely to result
in expenditure increases, which could ultimately threaten the
financial sustainability of the NHS (8).
None of the critics of NICE topic selection has so far
enumerated the case or defined a distinction between an ex-
isting or new technology. We, therefore, test two hypotheses,
that there is a bias toward new technologies and a bias to-
ward pharmaceuticals, by analyzing technologies that were
appraised in the first 100 published NICE appraisals.
METHODS
For a technology to be included in our analysis, it had to
have an appraisal published between March 2000 and June
2006 and be explicitly cited in the title or summary of the
guidance. These guidances correspond to a referral period
from Health Ministers to NICE between November 1999 to
June 2004. Appraisals may have included more than one
technology. For instance, in the guidance on the selection of
prostheses for primary total hip replacement (appraisal num-
ber 2), over sixty devices were assessed, but the comparison
was essentially between cemented, cementless, and hybrid
prostheses. The appraisal was, therefore, considered to con-
tain three technologies. Reviews of existing appraisals were
only included if the scope had altered and only technologies
additional to those originally appraised were counted.
We distinguished three major categories of technologies:
pharmaceuticals, devices, and procedures (diagnostic or ther-
apeutic), and one miscellaneous category for technologies
such as settings of care.
Existing and new technologies were defined according
to the time elapsed between launch and referral to NICE.
Technologies were defined as “new” if they were referred to
NICE before their launch, or if less than 3 years had elapsed
between their launch and their referral to NICE (Figure 1).
The rationale is that a new technology is one in the phase
of adoption that has only been available for clinical use for
a short time and will generally be in the launch or early
postmarketing stages. Typical diffusion rates would put this
timing at around 3 years (2;11). Technologies were defined
as “existing” if they were referred to NICE 3 or more years
after launch. We conducted a sensitivity analysis using 1- and
5-year postlaunch cutoff points (Figure 1).
Launch dates for pharmaceuticals were obtained from
the pharmaceutical database Adis R&D Insight (http://www.
adisinsight.com/) with a 20 percent random sample checked
with manufacturers to validate accuracy. For devices, the date
of availability outside a research setting in the United King-
dom was used as a proxy for the launch date. Information
was obtained directly from manufacturers or UK distributors,
except for devices that were launched pre-1994 (i.e., 5 years
before the first referral from the DH), when exact dates were
not required as they would be classed as existing technolo-
gies. For procedures, the date of first journal publication by
UK authors, obtained through Medline and Embase searches,
was used as a proxy for launch. The date of referral to NICE
was defined as the date at which a technology was formally
referred by Ministers to NICE. This information was sought
directly from the DH.
RESULTS
Pharmaceuticals account for 75 percent of the total number
of technologies considered in the 88 appraisals included in
our analysis (12 reviews were not included; Table 1). New
technologies make up 53 percent of appraised technologies
(Figure 2). This proportion is sensitive to the cutoff point
used: changing to 36 percent with the 1-year cutoff, and
67 percent with the 5-year cutoff. The proportion of new
technologies appraised is much greater for pharmaceuticals
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Table 1. Frequency and Proportion of Individual Technolo-
gies by Technology Type
No. of technologies
Appraisal type appraised (n= 159)
Pharmaceuticals 119 (74.8%)
Devices 22 (13.8%)
Procedures (diagnostic/therapeutic) 14 (8.8%)
Miscellaneous 4 (2.5%)
(which dominate the program) than for other technologies
(62 percent; sensitivity analysis 42 to 75 percent).
DISCUSSION
Our data suggest that the referral system to NICE favors the
appraisal of pharmaceuticals in preference to any other tech-
nology type and that approximately half of all technologies
and 62 percent of pharmaceuticals appraised can be con-
sidered as new. Although enumeration of the problem has
shown the criticism of a bias toward new technologies to be
unfounded when applied to the appraisal program overall, it
is true of pharmaceuticals. The domination of the program by
pharmaceuticals has been a feature from the outset, as shown
by an earlier analysis of the first thirty-two technology ap-
praisals where around two thirds of technology appraisals
were of pharmaceuticals (14).
One caveat is that the cutoff between new and existing
is subjective. With pharmaceuticals, the sensitivity analysis
found that a relatively large proportion of those initially cat-
egorized as existing, using a 3-year cutoff, were reclassified
as new using the 5-year cutoff. This result lends weight to
the finding of a bias toward new pharmaceuticals, because
even 5 years after launch, many pharmaceuticals may not be
fully diffused (4;11). At the other extreme, it is unlikely that
a technology would have completed its diffusion by 1-year
postlaunch, and in the majority of cases classifying a tech-
nology as old at 1-year postlaunch is unlikely to be realistic
(1). Nonpharmaceuticals typically diffuse more slowly (2).
A second caveat of our analysis of the proportion of new
technologies appraised is that, for every new technology ap-
praised, arguably there is one or more existing comparators
considered in the appraisal. However, although this argument
may be valid in some cases, many new technologies are ad-
ditions to current therapy rather than substitutes. In addition,
a strategy of appraising only new technologies risks never
considering the existing technologies in areas where no new
technology appears.
Although the appraisal program was never intended to
represent the “real world” in terms of the technological
Figure 2. Percentage of new technologies appraised by technology type.
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landscape, it is of interest to consider whether our findings re-
flect this. In the case of pharmaceuticals, given that less than
50 new chemical entities are approved each year (7), the de-
nominator for the number of new pharmaceuticals launched
into the market during our period of analysis (November 1996
to June 2004, inclusive of an additional 3-year diffusion pe-
riod before the first referral to NICE) could only amount to
a maximum of 400. There are more than 1,250 drug mono-
graphs listed in the British National Formulary. On this basis,
NICE has appraised 9.5 percent of all pharmaceuticals, 19
percent of the maximum number of new drugs, and 5 per-
cent of the estimated number of existing drugs (χ2 = 53.844;
p < .001; df = 1). In comparison, there are approximately
6,000 Office for Population Censuses and Surveys (OPCS)-
coded procedures, and around 1,100 product categories that
cover an estimated 50,000 medical devices (12). From this
perspective, proportionally, the appraisal program has ad-
dressed less than 0.1 percent of nonpharmaceuticals.
However, is the greater proportion of appraisals allo-
cated to pharmaceuticals, and especially to new pharmaceuti-
cals unreasonable? Arguably the policy objective was to keep
some balance between appraising new and existing technolo-
gies, and between pharmaceuticals and other technologies,
but not at the expense of failing to appraise important new
pharmaceuticals close to launch. NICE has been under in-
creasing pressure to appraise new technologies at or as close
to launch as possible to prevent inappropriate diffusion. New
pharmaceuticals in particular, have the potential to impact
on healthcare budgets quickly, because in general, they can
be prescribed by any doctor and usually require no special
systems or equipment for administration.
Different behavior from the industrial sponsors of tech-
nologies may also impact on the favoring of new pharmaceu-
ticals. Inclusion of a technology in NICE’s appraisal program
has important implications for its adoption and subsequent
diffusion, particularly since January 2002, when healthcare
providers were obliged to comply with NICE’s appraisal
recommendations (6). New nonpharmaceuticals tend to have
less commercial pressure behind them and make their initial
impact over a longer time frame than pharmaceuticals, often
because they require consideration of capital expenditure, or
need specialist training or equipment for utilization. Proce-
dures are also less likely to have industry supporting their
introduction, as they are often pioneered by clinicians.
Under-representation of new nonpharmaceuticals could
also be a product of the often incremental developments
associated with medical devices and procedures. As well
as reducing overall impact, the rate at which modifications
occur often means that each version of the technology has a
short life-span, making it more difficult to appraise and giving
the final appraisal a short shelf-life. Each modification could
make that technology new, but essentially the concept is old.
Arguments against the current dominance of new phar-
maceuticals in NICE’s appraisal program are that a continu-
ing bias toward new and expensive pharmaceuticals could set
up further financial problems for the health service and that
tightly controlling the introduction of innovations to prevent
inappropriate diffusion could stifle future development for
new patient indications (depending on whether NICE tends
to approve or limit the technologies it appraises).
CONCLUSIONS
Certainly, if the appraisal program of NICE is to meet its
original objective of representing technology types equally,
then the selection process will need to change. In addition,
if the health service is serious about targeting the removal of
ineffective technologies, the selection process may need to
pilot new identification methods, as previous initiatives
to identify obsolete or ineffective technologies have not led
to many published appraisals. NICE is constrained in terms
of the number of technologies it can appraise and to change
the emphasis from the new technology frontier to rationalize
the old could prove far more costly to the NHS than any
savings that could potentially be accrued. The introduction
of the single technology appraisal process may free up some
resources to concentrate on existing practices, and time will
tell if transferring responsibility for initial topic selection
from the disbanded Department of Health Advisory Com-
mittee for Topic Selection to NICE’s Consideration Panels
will have an impact on the configuration of the technologies
appraised in the future.
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